Story
Vitamin E
Last updated
In one pass Vitamin E's main job, and the one studied most thoroughly, is keeping the fats in cell membranes from being oxidized.
Educational content, not medical advice — consult a clinician.
Story path
Chapter 1
Eight forms, the liver keeps one
Vitamin E's main job, and the one studied most thoroughly, is keeping the fats in cell membranes from being oxidized. It works as an antioxidant brake the body carries with it. It dissolves in fat, so it lives inside membranes, and in the blood it rides on the particles that carry fat.
It is not one molecule but eight close relatives: 4 tocopherols and 4 tocotrienols. The one the body actually holds on to is alpha-tocopherol. The sorting happens in the liver. A protein that recognizes it specifically, the alpha-tocopherol transfer protein (alpha-TTP), loads it into the fat-carrying particles the liver sends into the blood; the other forms are more readily broken down and excreted.
That means a supplement labeled as mixed vitamin E, or a gamma-tocopherol formula, goes through the same filter once it reaches the liver. When the US Institute of Medicine set dietary intake recommendations in 2000, it too counted only alpha-tocopherol as vitamin E.
It is not one molecule but eight close relatives: 4 tocopherols and 4 tocotrienols. The one the body actually holds on to is alpha-tocopherol. The sorting happens in the liver. A protein that recognizes it specifically, the alpha-tocopherol transfer protein (alpha-TTP), loads it into the fat-carrying particles the liver sends into the blood; the other forms are more readily broken down and excreted.
That means a supplement labeled as mixed vitamin E, or a gamma-tocopherol formula, goes through the same filter once it reaches the liver. When the US Institute of Medicine set dietary intake recommendations in 2000, it too counted only alpha-tocopherol as vitamin E.
Mechanism · Why tocotrienols don't stay in blood
Tocotrienols come in four kinds, alpha, beta, gamma, and delta, and are most plentiful in palm oil, rice bran oil, and wheat germ. In test-tube and cell experiments, some of their antioxidant activities are stronger than those of tocopherols; whether they do anything useful in the human body is not yet clear.One reason is that filter in the liver. The alpha-tocopherol transfer protein (alpha-TTP) binds tocotrienols far less readily than alpha-tocopherol, so they are rarely loaded into the fat-carrying particles the liver releases (very-low-density lipoprotein, VLDL), and they circulate in the blood only briefly. There is also not enough clinical evidence to support tocotrienol supplements for healthy adults.
So eating a range of plant oils, nuts, and seeds brings in several forms along the way, and that is enough. Consider a supplement only when a doctor recommends one for a specific problem, and check which form it contains.
Chapter 2
Food · oils and seeds
Vitamin E is concentrated in plant oils, nuts, and seeds because it does the same job inside the plant: it keeps those oils from oxidizing. The richest sources are sunflower seeds (about 26 mg per 100 g), almonds (see Almonds), hazelnuts, and wheat germ, plus cooking oils such as sunflower and safflower oil. Avocado (about 2 mg per 100 g), spinach, and Chinese broccoli (gai lan) add some as well.
Many people assume olive oil is a good source of vitamin E. It is only middling (about 14 mg per 100 g) and not the best source. It is still a good oil, but for its monounsaturated fat and polyphenols, not for its vitamin E.
The most practical rule: swap a small handful of nuts or seeds in for some ultra-processed snacks, rather than adding a handful on top of what you already eat. Nuts carry a lot of energy, so adding them and swapping them in are two different things.
Many people assume olive oil is a good source of vitamin E. It is only middling (about 14 mg per 100 g) and not the best source. It is still a good oil, but for its monounsaturated fat and polyphenols, not for its vitamin E.
The most practical rule: swap a small handful of nuts or seeds in for some ultra-processed snacks, rather than adding a handful on top of what you already eat. Nuts carry a lot of energy, so adding them and swapping them in are two different things.
In practice · What d- and dl- mean on a label
The most important thing on a supplement label is one letter: d or dl. It separates natural from synthetic vitamin E.Natural (RRR-alpha-tocopherol)
Purified from plant oils, and made of a single stereoisomer (only one arrangement of its atoms in space)Label wording: d-alpha-tocopherol or RRR-alpha-tocopherolIts biological potency is defined as 1.0
Synthetic (all-rac-alpha-tocopherol)
A chemically made, equal mixture of 8 stereoisomers, of which only 1/8 is the natural oneLabel wording: dl-alpha-tocopherol or all-rac-alpha-tocopherol (note: dl, not d)The alpha-tocopherol transfer protein (alpha-TTP) in the liver recognizes only the half whose shape fits (4 of the 8, the so-called 2R forms), and the other half is quickly broken down. So by weight, the synthetic form has about 50% of the biological potency of the natural form
How to read on the label: the IU is a potency unit set by early animal experiments. It already accounts for part of the difference between the two forms, but not all of it. On the current US conversion, 1 IU of the natural form still supplies somewhat more alpha-tocopherol than 1 IU of the synthetic form; milligram for milligram, the natural form is worth about 2 times the synthetic. So 1 IU of synthetic is not the same as 1 IU of natural.
In practice:
From food: the form does not matter; the alpha-tocopherol in food is all the natural RRR formWhen a doctor recommends a supplement: check whether it says d or dl. When comparing two products, compare milligrams of alpha-tocopherol; the synthetic form takes about 2 times as much to match the natural oneMixed tocopherols on the label (with gamma-tocopherol and other forms): closer to what food contains, but alpha-TTP still keeps the alpha form first and the rest is broken down and excreted. Whether this brings any extra clinical benefit is unclear
Chapter 3
Stopping oxidation in cell membranes
Cell membranes hold many polyunsaturated fatty acids (), and one molecule of alone carries 6 double bonds. The hydrogens next to those double bonds are the easiest for a free radical to pull off. Once a fat molecule loses a hydrogen, it becomes a radical itself and pulls one from the next molecule. That is the chain reaction of lipid peroxidation, and as it runs on, the membrane is damaged.
Vitamin E dissolves right in the membrane's fat layer. It hands the hydrogen from the hydroxyl group (-OH) on its ring to the lipid peroxyl radical (LOO•) that is carrying the chain, and the chain stops there. Vitamin E itself becomes a tocopheroxyl radical (TO•), which is far less reactive than a lipid radical and does not pass the reaction on.
So vitamin E and omega-3 fats are not substitutes. One is building material and the other is protection: DHA makes the membrane softer and more fluid, and vitamin E keeps that DHA-rich membrane from being damaged by oxidation.
Vitamin E dissolves right in the membrane's fat layer. It hands the hydrogen from the hydroxyl group (-OH) on its ring to the lipid peroxyl radical (LOO•) that is carrying the chain, and the chain stops there. Vitamin E itself becomes a tocopheroxyl radical (TO•), which is far less reactive than a lipid radical and does not pass the reaction on.
So vitamin E and omega-3 fats are not substitutes. One is building material and the other is protection: DHA makes the membrane softer and more fluid, and vitamin E keeps that DHA-rich membrane from being damaged by oxidation.
Clinical · Vitamin E for inflamed fatty liver
The list of diseases vitamin E can actually treat is surprisingly short, and the clearest item on it is in the liver: metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH). It is the form of fatty liver that carries inflammation and can progress to scarring (fibrosis). The whole disease is called metabolic dysfunction-associated steatotic liver disease, (formerly NAFLD). The trial below used the NASH definition of its time.The PIVENS trial (Sanyal 2010, NEJM)
247 adults without diabetes whose NASH had been confirmed by liver biopsy were randomized to 800 a day of natural vitamin E, pioglitazone (a diabetes drug), or placebo for 96 weeksImprovement in liver tissue: about 43% with vitamin E versus 19% with placeboLiver enzymes ( and ) also fellBut fibrosis scores did not improve, and fibrosis is the measure that decides whether the liver later moves toward cirrhosisThis is one trial, and its result covers only adults without diabetes whose disease was confirmed by biopsy
The American Association for the Study of Liver Diseases (AASLD) guidance of 2018
Adults without diabetes and with biopsy-confirmed disease: 800 IU a day may be considered, after the risks and benefits are discussed with the patientPeople with diabetes, people who have not had a biopsy, and people who already have cirrhosis: not recommended as treatment until more data are available
Why it might help (a hypothesis): one core problem in this kind of hepatitis is that mitochondria produce too many reactive oxygen species, which injure liver cells. Vitamin E blocks lipid peroxidation in liver cell membranes and may also dampen inflammatory signals. This is reasoning from the mechanism; it has not been shown directly that this is why it works.
The cost of high doses over the long term
A possible small rise in bleeding risk, because it interferes with clotting that depends on vitamin KA possible rise in prostate cancer risk: in the SELECT trial (Klein 2011, JAMA), middle-aged and older men with no sign of prostate cancer took 400 IU a day of synthetic vitamin E, and by a median follow-up of about 7 years prostate cancer was 17% more common ( 1.17, P=0.008)So long-term use of 800 IU a day belongs under a doctor's supervision, not in a self-bought supplement
In practice
It is not a general liver protector: fatty liver with fat buildup but no inflammation does not call for vitamin EConfirmed steatohepatitis without diabetes: whether to take 800 IU a day is the doctor's decisionAt every stage, the first-line step is weight loss of 7–10% of body weight; vitamin E is only an add-on
chalasani-2018-aasld-nafldsanyal-2010-pivens
Chapter 4
Recycled by vitamin C
After vitamin E stops a free radical, it becomes a tocopheroxyl radical (TO•) itself. It does not stay that way: at the boundary between membrane and water, vitamin C hands it back an electron, and it turns into usable vitamin E again.
This is a relay, and every leg needs someone to take the baton:
1. In the watery phase, vitamin C restores TO• to alpha-tocopherol and becomes dehydroascorbate (that is, oxidized vitamin C)
2. Glutathione, the most abundant small antioxidant molecule in the cell, restores the oxidized vitamin C
3. The cell then uses , a coenzyme that carries reducing power, to restore the used glutathione
So antioxidant defense is not more of one molecule is better; it is a cycle in which several systems take turns restoring each other. In the test tube, when vitamin E is piled up on its own and reducers such as vitamin C run short, TO• accumulates and starts promoting oxidation instead. How much this matters in the human body has not been measured directly. It is one hypothesis for why the large trials came up empty, not a settled answer: the Heart Protection Study (2002) gave vitamin E together with vitamin C and beta-carotene and still saw no drop in cardiovascular events.
This is a relay, and every leg needs someone to take the baton:
1. In the watery phase, vitamin C restores TO• to alpha-tocopherol and becomes dehydroascorbate (that is, oxidized vitamin C)
2. Glutathione, the most abundant small antioxidant molecule in the cell, restores the oxidized vitamin C
3. The cell then uses , a coenzyme that carries reducing power, to restore the used glutathione
So antioxidant defense is not more of one molecule is better; it is a cycle in which several systems take turns restoring each other. In the test tube, when vitamin E is piled up on its own and reducers such as vitamin C run short, TO• accumulates and starts promoting oxidation instead. How much this matters in the human body has not been measured directly. It is one hypothesis for why the large trials came up empty, not a settled answer: the Heart Protection Study (2002) gave vitamin E together with vitamin C and beta-carotene and still saw no drop in cardiovascular events.
Clinical · Who actually runs short of vitamin E
True vitamin E deficiency is almost never seen in healthy people, but it does occur in a few well-defined clinical situations.1. Fat malabsorption
Biliary atresia (in infants): with no bile, none of the fat-soluble vitamins A, D, E, and K can be absorbedCystic fibrosis: the pancreas does not release enough digestive enzymes, so fat is not digestedChronic pancreatitis, Crohn's disease, and short bowel syndromeAfter gastric bypass surgery
2. Inherited diseases
Ataxia with vitamin E deficiency (AVED): mutations in the TTPA gene disable the alpha-tocopherol transfer protein (alpha-TTP), so intake is normal but vitamin E in the blood plasma is extremely lowTypical features: worsening ataxia (unsteady walking and poor coordination, from degeneration in the spinal cord and cerebellum), together with damage to the peripheral nerves and retinitis pigmentosaIt looks very much like Friedreich's ataxia, and only a plasma vitamin E test tells them apartFound early, with lifelong high-dose supplementation arranged by a doctor, its progression can be stopped and some symptoms improve; found late, the nerve damage already done often cannot be reversedAbetalipoproteinemia: a mutation in the MTP gene leaves the body unable to build the particles that carry fat (chylomicrons and VLDL), so all the fat-soluble vitamins A, D, E, and K run short
3. Preterm infants: small stores, plus red cell membranes rich in polyunsaturated fat, make them prone to hemolysis (red cells breaking apart)
Signs of severe deficiency
Cerebellar ataxia, with loss of position sense and vibration senseRetinal damageHemolytic anemia (red cell membranes oxidize easily and burst)Muscle weakness
How it is tested: measure plasma alpha-tocopherol and calculate the ratio of alpha-tocopherol to blood lipids (total cholesterol). Vitamin E travels in the blood on lipoproteins, so people with high blood lipids read high, and the value has to be corrected.
Why it is so rare: with a normal diet, a normal gut, and a normal lipoprotein system, vitamin E is almost never low enough to cause disease. That is the opposite of water-soluble vitamins such as folate, which have shallow stores and fast turnover (B12 is the exception among the water-soluble vitamins; the liver can hold years of it). Fat-soluble vitamin E has deep stores and slow turnover, so a true deficiency almost always has a specific medical cause.
Chapter 5
High-dose pills: risks and trials
Vitamin E's mechanism looks elegant in the lab: it stops lipid oxidation in membranes and can be restored by vitamin C to work again. So people reasoned that taking a bit more would mean less heart disease and cancer. Several large randomized trials tested that idea, and every one came up empty:
HOPE: adults aged 55 and over at high cardiovascular risk took 400 a day; heart attacks, strokes, and cardiovascular deaths did not fallHeart Protection Study: adults who already had coronary disease, other blocked arteries, or diabetes took vitamin E together with vitamin C and beta-carotene; events did not fall eitherSELECT: middle-aged and older men with no sign of prostate cancer took 400 IU a day, and prostate cancer rose instead of falling
The lesson is not that vitamin E is useless. It is that a mechanism that makes sense and taking it means less disease are separated by an entire human body, and only trials can answer the second question.
What really calls for care is high-dose pills. They may interfere with vitamin K-dependent clotting, and bleeding risk is higher when they are combined with anticoagulants such as warfarin. The US tolerable upper intake level () for adults is 1000 mg a day (counted as supplemental alpha-tocopherol). The people who need a supplement are mainly those with fat malabsorption or an inherited alpha-TTP defect; for everyone else a small handful of nuts or seeds a day (about 30 g) is enough.
HOPE: adults aged 55 and over at high cardiovascular risk took 400 a day; heart attacks, strokes, and cardiovascular deaths did not fallHeart Protection Study: adults who already had coronary disease, other blocked arteries, or diabetes took vitamin E together with vitamin C and beta-carotene; events did not fall eitherSELECT: middle-aged and older men with no sign of prostate cancer took 400 IU a day, and prostate cancer rose instead of falling
The lesson is not that vitamin E is useless. It is that a mechanism that makes sense and taking it means less disease are separated by an entire human body, and only trials can answer the second question.
What really calls for care is high-dose pills. They may interfere with vitamin K-dependent clotting, and bleeding risk is higher when they are combined with anticoagulants such as warfarin. The US tolerable upper intake level () for adults is 1000 mg a day (counted as supplemental alpha-tocopherol). The people who need a supplement are mainly those with fat malabsorption or an inherited alpha-TTP defect; for everyone else a small handful of nuts or seeds a day (about 30 g) is enough.
Evidence · What each large trial actually found
Vitamin E is the textbook case of a mechanism that makes sense and clinical endpoints that came up empty. Each trial below is described by who was studied, what they were given, and what was found.Cardiovascular prevention
HOPE (Yusuf 2000, NEJM): 9541 adults aged 55 and over at high cardiovascular risk took 400 of natural-source vitamin E a day or placebo for a mean of 4.5 years. The combined endpoint of heart attack, stroke, and cardiovascular death was 16.2% versus 15.5% ( 1.05), and none of the three differed when looked at separatelyHOPE-TOO (Lonn 2005, JAMA): an extended follow-up of HOPE, median 7 years. The main cardiovascular endpoint still did not differ; heart-failure events were 13% more common (RR 1.13, P=0.03), and hospital admissions for heart failure were 21% more common (RR 1.21)Heart Protection Study (2002, Lancet): 20,536 high-risk adults in the UK (with coronary disease, other blocked arteries, or diabetes) took 600 mg of vitamin E, 250 mg of vitamin C, and 20 mg of beta-carotene a day, with 5 years of treatment planned. Blood alpha-tocopherol roughly doubled, yet major vascular events were identical: 22.5% versus 22.5%Physicians' Health Study II (Sesso 2008, JAMA): 14,641 US male physicians aged 50 and over took 400 IU every other day for a mean of 8 years. Major cardiovascular events did not change ( 1.01); hemorrhagic stroke was 74% more common (HR 1.74, P=0.04)
Cancer prevention
SELECT (Lippman 2009; Klein 2011, JAMA): 35,533 middle-aged and older men with no sign of prostate cancer (in the US, Canada, and Puerto Rico) took 400 IU of synthetic vitamin E a day. The first analysis found no preventive effect at all, and the supplements were then stopped. With follow-up continued to a median of about 7 years, prostate cancer was 17% more common in the vitamin E group (HR 1.17, P=0.008), which works out to 76 versus 65 cases per 1000 men. Among nutrition prevention trials, it is one of the most unexpected results in the wrong directionATBC (1994, NEJM): male smokers aged 50–69 in Finland took 50 mg of alpha-tocopherol a day, followed for 5–8 years; lung cancer did not fall. Deaths from hemorrhagic stroke were somewhat more common, while prostate cancer was somewhat less common. That unexpected prostate signal is what led to SELECT, which tested it directly and found the opposite direction
When the trials are pooled: the Miller 2005 found slightly higher all-cause mortality in trials that gave 400 IU a day or more. The authors themselves noted that most of these high-dose trials were small and enrolled people with chronic diseases, so whether the finding applies to healthy adults is uncertain.
Why the mechanism failed to predict the outcome (several explanations, all still hypotheses)
Antioxidant activity in a test tube is not the same as the body's overall redox balanceSome reactive oxygen is part of how cells signal to each other, and suppressing it across the board may not be good (the reductive stress hypothesis)A single antioxidant cannot replace a whole network: vitamin E, vitamin C, glutathione, and selenium, plus enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx)Heart attacks and cancer have many causes, and a single-point intervention cannot move them
Uses that still hold
Biopsy-confirmed steatohepatitis in adults without diabetes (the PIVENS trial, covered in detail in the cell membrane chapter)Correcting a true deficiency (fat malabsorption, AVED)Use on the skin (as an aid against sun damage, with weak evidence)
What this teaches
Jumping straight from the mechanism makes sense to it works in patients is the most common leap in nutrition, and the most expensive oneLarge randomized trials are indispensable; without them, a mechanism story is not enough to trustCurrent nutrition advice puts more weight on dietary patterns (DASH, the Mediterranean diet) and less on single high-dose supplements, and this set of negative trials of vitamin E, vitamin C, and beta-carotene is one reason why
atbc-1994-nejm
References · 11
- National Institutes of Health, Office of Dietary Supplements. (2021). Vitamin E — Fact Sheet for Health Professionals. ods.od.nih.gov/factsheets/VitaminE-HealthProfessional
- Institute of Medicine. (2000). Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. National Academies Press. www.ncbi.nlm.nih.gov/books/NBK225483
- Mozaffarian, D., & Wu, J. H. Y. (2011). Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. Journal of the American College of Cardiology, 58(20), 2047–2067. 10.1016/j.jacc.2011.06.063
- Yusuf, S., Dagenais, G., Pogue, J., Bosch, J., & Sleight, P. (2000). Vitamin E supplementation and cardiovascular events in high-risk patients (HOPE). The New England Journal of Medicine, 342(3), 154–160. 9,541 high-risk adults aged >= 55 (2,545 women, 6,996 men), 400 IU natural-source vitamin E daily or placebo for a mean of 4.5 years (2 x 2 factorial with ramipril). Primary composite (MI, stroke, cardiovascular death) 16.2% vs 15.5% (RR 1.05, 0.95-1.16); no differences in cardiovascular death, MI or stroke (abstract, PMID 10639540). 10.1056/NEJM200001203420302
- Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005). Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine, 142(1), 37–46. 10.7326/0003-4819-142-1-200501040-00110
- Klein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., et al. (2011). Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 306(14), 1549-1556. Among 35,533 men, vitamin E 400 IU/day significantly increased prostate cancer risk (about 17% relative increase; 76 vs 65 cases per 1,000). 10.1001/jama.2011.1437
- National Institutes of Health, Office of Dietary Supplements. (2021). Vitamin C — Fact Sheet for Health Professionals. ods.od.nih.gov/factsheets/VitaminC-HealthProfessional
- Heart Protection Study Collaborative Group. (2002). MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. The Lancet, 360(9326), 23-33. Antioxidant vitamins (600 mg E + 250 mg C + 20 mg beta-carotene) vs placebo: major vascular events 22.5% vs 22.5%; stroke 5.0% vs 5.0%. Not the source of the 74% haemorrhagic-stroke figure. 10.1016/S0140-6736(02)09328-5
- Lonn, E., Bosch, J., Yusuf, S., Sheridan, P., Pogue, J., Arnold, J. M. O., et al. (2005). Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA, 293(11), 1338-1347. HOPE-TOO extension, median 7.0 y. All heart-failure events RR 1.13 (1.01-1.26); hospitalisation for heart failure RR 1.21 (1.00-1.47). Primary CV composite remained null. 10.1001/jama.293.11.1338
- Sesso, H. D., Buring, J. E., Christen, W. G., Kurth, T., Belanger, C., MacFadyen, J., et al. (2008). Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA, 300(18), 2123-2133. Vitamin E 400 IU every other day: major CV events null (HR 1.01); haemorrhagic stroke HR 1.74 (1.04-2.91, P=0.04). Do not hang the 2012 PHS-II multivitamin paper (sesso-2012-phs2-cvd) for this number. 10.1001/jama.2008.600
- Lippman, S. M., et al. (2009). Effect of selenium and vitamin E on risk of prostate cancer (SELECT): a randomized controlled trial. JAMA, 301(1), 39–51. 35,533 men (African American 50 or older, others 55 or older; PSA 4 ng/mL or less) randomised to selenium 200 micrograms/day (L-selenomethionine), vitamin E 400 IU/day, both, or placebo. Median follow-up 5.46 years at the 23 October 2008 data cut. Prostate cancer HR (99% CI): vitamin E 1.13 (0.95-1.35), selenium 1.04, combination 1.05 - none significant; no other prespecified cancer end point differed. Type 2 diabetes with selenium RR 1.07 (0.94-1.22), P = .16, not significant (abstract, PMID 19066370). 10.1001/jama.2008.864